NRG 200 Pharmacology for Human Caring Nursing - Final
Exam Prep Document | 2026/2027 Edition | 200 Verified
Questions - 170 Questions with Answers
NRG 200 Pharmacology for Human Caring Nursing Final Exam 2026-170 QUESTIONS AND ANSWERS
ALREADY GRADED A+. 100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document is meticulously designed for nursing students enrolled
in NRG 200 Pharmacology for Human Caring. It contains 200 verified multiple-choice questions that
mirror the format and rigor of the final exam. Each question is accompanied by the correct answer and
a detailed explanation in italics, ensuring a deep understanding of pharmacological principles within
the context of human caring. This resource is essential for achieving a top grade and mastering the
integration of pharmacology with compassionate nursing practice.
Key Features:
Pharmacokinetics and pharmacodynamics
Drug classifications and mechanisms of action
Nursing implications and patient education
Safe medication administration and dosage calculations
Adverse effects, contraindications, and drug interactions
Human caring perspectives in pharmacological interventions
Updates for 2026:
- Revised to reflect the latest 2026-2027 NCLEX-RN test plan and pharmacology guidelines
- Incorporated updated safety protocols and black box warnings from the FDA
- Enhanced rationales to emphasize the human caring framework in nursing
- Added new questions on emerging pharmacologic therapies and precision medicine
- Aligned content with current evidence-based practice and quality improvement initiatives
Abstract:
This exam preparation document for NRG 200 Pharmacology for Human Caring Nursing is a meticulously curated
collection of 200 multiple-choice questions designed to assess and reinforce the essential pharmacological
knowledge required for safe and compassionate nursing practice. The questions are organized into content areas
that reflect the core competencies of the course, including pharmacokinetics, pharmacodynamics, drug
classifications, and the nursing process as applied to medication administration. Each question is accompanied by
a correct answer and a comprehensive explanation in italics, which not only clarifies the rationale but also
integrates the principles of human caring, emphasizing the holistic approach to patient care. The document is
updated to align with the 2026-2027 academic year and the latest NCLEX-RN test plan, ensuring that students are
prepared for both their final exam and their future licensure examination. By engaging with this resource, students
will develop a robust understanding of pharmacological principles and their application in diverse clinical
scenarios, ultimately enhancing their ability to provide patient-centered care that respects the dignity and
uniqueness of each individual. The inclusion of detailed rationales and nursing implications makes this document
an invaluable tool for active learning and critical thinking, promoting the integration of theory and practice in the
art and science of nursing.
Keywords:
Pharmacology, Human Caring, Nursing, NCLEX-RN, Medication Administration, Drug Interactions, Patient
Education, Exam Prep
Answer Format:
Page 1
,Each question is presented in a standard multiple-choice format with four options. The correct answer is clearly
indicated, and an explanation in italics follows, detailing the rationale for the correct choice and why the distractors
are incorrect. This format facilitates active learning and reinforces key pharmacological concepts.
Compliance Checklist:
Aligned with the latest NCLEX-RN test plan and 2026-2027 guidelines
Includes 200 verified questions with correct answers and explanations
Covers all major content areas of NRG 200 Pharmacology for Human Caring
Rationales integrate the human caring framework and evidence-based practice
Suitable for self-assessment, group study, and exam review
Content Area Overview:
Content Area Questions Key Topics Weight
Pharmacokinetics and 1-25 Absorption, Distribution, Metabolism, 12.5%
Pharmacodynamics Excretion, Receptor Theory
Autonomic Nervous System 26-50 Cholinergics, Anticholinergics, Adrenergics, 12.5%
Drugs Adrenergic Blockers
Cardiovascular and Renal Drugs 51-75 Antihypertensives, Diuretics, Cardiac 12.5%
Glycosides, Antiarrhythmics
Central Nervous System Drugs 76-100 Sedatives, Antidepressants, Antipsychotics, 12.5%
Anticonvulsants
Endocrine and Metabolic Drugs 101-125 Insulin, Oral Hypoglycemics, 12.5%
Corticosteroids, Thyroid Agents
Antimicrobials and 126-150 Antibiotics, Antivirals, Antifungals, 12.5%
Anti-infectives Antituberculars
Cancer and Immunomodulators 151-175 Chemotherapy, Targeted Therapy, 12.5%
Immunosuppressants, Biologics
Special Populations and Nursing 176-200 Pediatrics, Geriatrics, Pregnancy, Cultural 12.5%
Considerations Considerations, Patient Education
Page 2
,Q1. A patient on long-term warfarin therapy is prescribed a course of oral
fluconazole for a fungal infection. Which pharmacokinetic interaction is most likely to
occur, and what adjustment is required?
A. Fluconazole inhibits CYP2C9, increasing warfarin levels; reduce warfarin dose and
monitor INR.
B. Fluconazole induces CYP3A4, decreasing warfarin levels; increase warfarin dose.
C. Fluconazole displaces warfarin from plasma proteins, causing transient toxicity; no
dose change needed.
D. Fluconazole increases renal excretion of warfarin; monitor renal function and adjust
accordingly.
Correct Answer: A. Fluconazole inhibits CYP2C9, increasing warfarin levels; reduce
warfarin dose and monitor INR.
Rationale: Fluconazole is a potent inhibitor of CYP2C9, the primary enzyme metabolizing
the S-enantiomer of warfarin. This inhibition leads to elevated warfarin plasma
concentrations and increased anticoagulant effect, necessitating a dose reduction and
close INR monitoring to prevent bleeding.
Why Wrong:
B - Fluconazole is an inhibitor, not an inducer, of CYP enzymes; it does not increase
warfarin metabolism.
C - Although protein binding displacement can occur with some drugs, the primary
interaction is metabolic inhibition, and dose adjustment is always required.
D - Warfarin is primarily metabolized hepatically; renal excretion is not a significant
pathway, and this is not the main interaction with fluconazole.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 86
(Antifungals) & Ch. 34 (Anticoagulants).
Q2. A patient with type 2 diabetes is started on metformin and later prescribed a
sulfonylurea. Which statement best explains the complementary mechanism of action
of this combination?
A. Metformin enhances insulin sensitivity, while sulfonylureas stimulate insulin
secretion from pancreatic beta cells.
B. Metformin increases insulin secretion, while sulfonylureas decrease hepatic glucose
production.
C. Both drugs act by delaying carbohydrate absorption in the gastrointestinal tract.
D. Metformin promotes glucose excretion in urine, while sulfonylureas block glucagon
receptors.
Correct Answer: A. Metformin enhances insulin sensitivity, while sulfonylureas
stimulate insulin secretion from pancreatic beta cells.
Page 3
, Rationale: Metformin primarily reduces hepatic glucose production and improves
peripheral insulin sensitivity, whereas sulfonylureas bind to SUR1 receptors on pancreatic
beta cells to stimulate endogenous insulin secretion. This complementary action addresses
both insulin resistance and insulin deficiency, improving glycemic control.
Why Wrong:
B - The actions are reversed: metformin does not increase insulin secretion, and
sulfonylureas do not decrease hepatic glucose production as a primary effect.
C - Delaying carbohydrate absorption is the mechanism of alpha-glucosidase
inhibitors, not metformin or sulfonylureas.
D - Metformin does not cause urinary glucose excretion in therapeutic use;
sulfonylureas do not block glucagon receptors.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 42
(Antidiabetic Drugs).
Q3. A patient receiving an opioid agonist-antagonist (e.g., pentazocine) develops
severe respiratory depression. Naloxone is administered. What is the most
appropriate nursing consideration regarding the response to naloxone?
A. A lower dose of naloxone may be needed, and the response may be incomplete due
to the ceiling effect of agonist-antagonists.
B. Standard doses of naloxone will fully reverse respiratory depression because all
opioids act on mu receptors.
C. Naloxone is contraindicated because it may precipitate withdrawal and worsen
respiratory depression.
D. Naloxone will have no effect because agonist-antagonists do not bind to opioid
receptors.
Correct Answer: A. A lower dose of naloxone may be needed, and the response may
be incomplete due to the ceiling effect of agonist-antagonists.
Rationale: Agonist-antagonist opioids like pentazocine have a ceiling effect on respiratory
depression, but they also have high affinity for mu receptors where they act as weak
antagonists. Naloxone, a pure antagonist, can reverse their effects, but higher doses may
be required, and the response can be incomplete due to the complex receptor binding.
Additionally, naloxone may precipitate withdrawal symptoms.
Why Wrong:
B - Standard naloxone doses may not be sufficient for agonist-antagonists; the
response is not always complete.
C - Naloxone is not contraindicated; it is the antidote for opioid-induced respiratory
depression, though it may cause withdrawal.
D - Agonist-antagonists do bind to opioid receptors, and naloxone can reverse their
effects.
Page 4
Exam Prep Document | 2026/2027 Edition | 200 Verified
Questions - 170 Questions with Answers
NRG 200 Pharmacology for Human Caring Nursing Final Exam 2026-170 QUESTIONS AND ANSWERS
ALREADY GRADED A+. 100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document is meticulously designed for nursing students enrolled
in NRG 200 Pharmacology for Human Caring. It contains 200 verified multiple-choice questions that
mirror the format and rigor of the final exam. Each question is accompanied by the correct answer and
a detailed explanation in italics, ensuring a deep understanding of pharmacological principles within
the context of human caring. This resource is essential for achieving a top grade and mastering the
integration of pharmacology with compassionate nursing practice.
Key Features:
Pharmacokinetics and pharmacodynamics
Drug classifications and mechanisms of action
Nursing implications and patient education
Safe medication administration and dosage calculations
Adverse effects, contraindications, and drug interactions
Human caring perspectives in pharmacological interventions
Updates for 2026:
- Revised to reflect the latest 2026-2027 NCLEX-RN test plan and pharmacology guidelines
- Incorporated updated safety protocols and black box warnings from the FDA
- Enhanced rationales to emphasize the human caring framework in nursing
- Added new questions on emerging pharmacologic therapies and precision medicine
- Aligned content with current evidence-based practice and quality improvement initiatives
Abstract:
This exam preparation document for NRG 200 Pharmacology for Human Caring Nursing is a meticulously curated
collection of 200 multiple-choice questions designed to assess and reinforce the essential pharmacological
knowledge required for safe and compassionate nursing practice. The questions are organized into content areas
that reflect the core competencies of the course, including pharmacokinetics, pharmacodynamics, drug
classifications, and the nursing process as applied to medication administration. Each question is accompanied by
a correct answer and a comprehensive explanation in italics, which not only clarifies the rationale but also
integrates the principles of human caring, emphasizing the holistic approach to patient care. The document is
updated to align with the 2026-2027 academic year and the latest NCLEX-RN test plan, ensuring that students are
prepared for both their final exam and their future licensure examination. By engaging with this resource, students
will develop a robust understanding of pharmacological principles and their application in diverse clinical
scenarios, ultimately enhancing their ability to provide patient-centered care that respects the dignity and
uniqueness of each individual. The inclusion of detailed rationales and nursing implications makes this document
an invaluable tool for active learning and critical thinking, promoting the integration of theory and practice in the
art and science of nursing.
Keywords:
Pharmacology, Human Caring, Nursing, NCLEX-RN, Medication Administration, Drug Interactions, Patient
Education, Exam Prep
Answer Format:
Page 1
,Each question is presented in a standard multiple-choice format with four options. The correct answer is clearly
indicated, and an explanation in italics follows, detailing the rationale for the correct choice and why the distractors
are incorrect. This format facilitates active learning and reinforces key pharmacological concepts.
Compliance Checklist:
Aligned with the latest NCLEX-RN test plan and 2026-2027 guidelines
Includes 200 verified questions with correct answers and explanations
Covers all major content areas of NRG 200 Pharmacology for Human Caring
Rationales integrate the human caring framework and evidence-based practice
Suitable for self-assessment, group study, and exam review
Content Area Overview:
Content Area Questions Key Topics Weight
Pharmacokinetics and 1-25 Absorption, Distribution, Metabolism, 12.5%
Pharmacodynamics Excretion, Receptor Theory
Autonomic Nervous System 26-50 Cholinergics, Anticholinergics, Adrenergics, 12.5%
Drugs Adrenergic Blockers
Cardiovascular and Renal Drugs 51-75 Antihypertensives, Diuretics, Cardiac 12.5%
Glycosides, Antiarrhythmics
Central Nervous System Drugs 76-100 Sedatives, Antidepressants, Antipsychotics, 12.5%
Anticonvulsants
Endocrine and Metabolic Drugs 101-125 Insulin, Oral Hypoglycemics, 12.5%
Corticosteroids, Thyroid Agents
Antimicrobials and 126-150 Antibiotics, Antivirals, Antifungals, 12.5%
Anti-infectives Antituberculars
Cancer and Immunomodulators 151-175 Chemotherapy, Targeted Therapy, 12.5%
Immunosuppressants, Biologics
Special Populations and Nursing 176-200 Pediatrics, Geriatrics, Pregnancy, Cultural 12.5%
Considerations Considerations, Patient Education
Page 2
,Q1. A patient on long-term warfarin therapy is prescribed a course of oral
fluconazole for a fungal infection. Which pharmacokinetic interaction is most likely to
occur, and what adjustment is required?
A. Fluconazole inhibits CYP2C9, increasing warfarin levels; reduce warfarin dose and
monitor INR.
B. Fluconazole induces CYP3A4, decreasing warfarin levels; increase warfarin dose.
C. Fluconazole displaces warfarin from plasma proteins, causing transient toxicity; no
dose change needed.
D. Fluconazole increases renal excretion of warfarin; monitor renal function and adjust
accordingly.
Correct Answer: A. Fluconazole inhibits CYP2C9, increasing warfarin levels; reduce
warfarin dose and monitor INR.
Rationale: Fluconazole is a potent inhibitor of CYP2C9, the primary enzyme metabolizing
the S-enantiomer of warfarin. This inhibition leads to elevated warfarin plasma
concentrations and increased anticoagulant effect, necessitating a dose reduction and
close INR monitoring to prevent bleeding.
Why Wrong:
B - Fluconazole is an inhibitor, not an inducer, of CYP enzymes; it does not increase
warfarin metabolism.
C - Although protein binding displacement can occur with some drugs, the primary
interaction is metabolic inhibition, and dose adjustment is always required.
D - Warfarin is primarily metabolized hepatically; renal excretion is not a significant
pathway, and this is not the main interaction with fluconazole.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 86
(Antifungals) & Ch. 34 (Anticoagulants).
Q2. A patient with type 2 diabetes is started on metformin and later prescribed a
sulfonylurea. Which statement best explains the complementary mechanism of action
of this combination?
A. Metformin enhances insulin sensitivity, while sulfonylureas stimulate insulin
secretion from pancreatic beta cells.
B. Metformin increases insulin secretion, while sulfonylureas decrease hepatic glucose
production.
C. Both drugs act by delaying carbohydrate absorption in the gastrointestinal tract.
D. Metformin promotes glucose excretion in urine, while sulfonylureas block glucagon
receptors.
Correct Answer: A. Metformin enhances insulin sensitivity, while sulfonylureas
stimulate insulin secretion from pancreatic beta cells.
Page 3
, Rationale: Metformin primarily reduces hepatic glucose production and improves
peripheral insulin sensitivity, whereas sulfonylureas bind to SUR1 receptors on pancreatic
beta cells to stimulate endogenous insulin secretion. This complementary action addresses
both insulin resistance and insulin deficiency, improving glycemic control.
Why Wrong:
B - The actions are reversed: metformin does not increase insulin secretion, and
sulfonylureas do not decrease hepatic glucose production as a primary effect.
C - Delaying carbohydrate absorption is the mechanism of alpha-glucosidase
inhibitors, not metformin or sulfonylureas.
D - Metformin does not cause urinary glucose excretion in therapeutic use;
sulfonylureas do not block glucagon receptors.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 42
(Antidiabetic Drugs).
Q3. A patient receiving an opioid agonist-antagonist (e.g., pentazocine) develops
severe respiratory depression. Naloxone is administered. What is the most
appropriate nursing consideration regarding the response to naloxone?
A. A lower dose of naloxone may be needed, and the response may be incomplete due
to the ceiling effect of agonist-antagonists.
B. Standard doses of naloxone will fully reverse respiratory depression because all
opioids act on mu receptors.
C. Naloxone is contraindicated because it may precipitate withdrawal and worsen
respiratory depression.
D. Naloxone will have no effect because agonist-antagonists do not bind to opioid
receptors.
Correct Answer: A. A lower dose of naloxone may be needed, and the response may
be incomplete due to the ceiling effect of agonist-antagonists.
Rationale: Agonist-antagonist opioids like pentazocine have a ceiling effect on respiratory
depression, but they also have high affinity for mu receptors where they act as weak
antagonists. Naloxone, a pure antagonist, can reverse their effects, but higher doses may
be required, and the response can be incomplete due to the complex receptor binding.
Additionally, naloxone may precipitate withdrawal symptoms.
Why Wrong:
B - Standard naloxone doses may not be sufficient for agonist-antagonists; the
response is not always complete.
C - Naloxone is not contraindicated; it is the antidote for opioid-induced respiratory
depression, though it may cause withdrawal.
D - Agonist-antagonists do bind to opioid receptors, and naloxone can reverse their
effects.
Page 4
